236 related articles for article (PubMed ID: 23440162)
1. Diffusion of botulinum toxins.
Brodsky MA; Swope DM; Grimes D
Tremor Other Hyperkinet Mov (N Y); 2012; 2():. PubMed ID: 23440162
[TBL] [Abstract][Full Text] [Related]
2. Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.
Thomas AJ; Larson MO; Braden S; Cannon RB; Ward PD
JAMA Facial Plast Surg; 2018 Mar; 20(2):141-147. PubMed ID: 28973094
[TBL] [Abstract][Full Text] [Related]
3. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the spread of three botulinum toxin type A preparations.
Kerscher M; Roll S; Becker A; Wigger-Alberti W
Arch Dermatol Res; 2012 Mar; 304(2):155-61. PubMed ID: 22002325
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of biological activity of four botulinum toxin type A preparations in mice.
Chung ME; Song DH; Park JH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):155-64. PubMed ID: 23301819
[TBL] [Abstract][Full Text] [Related]
6. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR
Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type-A preparations are not the same medications - basic science (Part 1).
Car H; Bogucki A; Bonikowski M; Dec-Ćwiek M; Drużdż A; Koziorowski D; Rudzińska-Bar M; Sarzyńska-Długosz I; Sławek J
Neurol Neurochir Pol; 2021; 55(2):133-140. PubMed ID: 33797747
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type A for facial wrinkles.
Camargo CP; Xia J; Costa CS; Gemperli R; Tatini MD; Bulsara MK; Riera R
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD011301. PubMed ID: 34224576
[TBL] [Abstract][Full Text] [Related]
9. Diffusion, spread, and migration of botulinum toxin.
Ramirez-Castaneda J; Jankovic J; Comella C; Dashtipour K; Fernandez HH; Mari Z
Mov Disord; 2013 Nov; 28(13):1775-83. PubMed ID: 23868503
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice.
Prager W; Huber-Vorländer J; Taufig AZ; Imhof M; Kühne U; Weissberg R; Kuhr LP; Rippmann V; Philipp-Dormston WG; Proebstle TM; Roth C; Kerscher M; Ulmann C; Pavicic T
Clin Cosmet Investig Dermatol; 2012; 5():53-8. PubMed ID: 22791996
[TBL] [Abstract][Full Text] [Related]
11. A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.
Wilson AJ; Chang B; Taglienti AJ; Chin BC; Chang CS; Folsom N; Percec I
Plast Reconstr Surg; 2016 May; 137(5):1424-1433. PubMed ID: 27119918
[TBL] [Abstract][Full Text] [Related]
12. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
Han Y; Stevens AL; Dashtipour K; Hauser RA; Mari Z
J Neurol; 2016 Apr; 263(4):772-80. PubMed ID: 26914922
[TBL] [Abstract][Full Text] [Related]
13. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
Jimenez-Shahed J
Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
[TBL] [Abstract][Full Text] [Related]
14. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
Chen JJ; Dashtipour K
Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
[TBL] [Abstract][Full Text] [Related]
15. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
Shome D; Kapoor R; Khare S
J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
17. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice.
Carruthers A; Kane MA; Flynn TC; Huang P; Kim SD; Solish N; Kaeuper G
Dermatol Surg; 2013 Mar; 39(3 Pt 2):493-509. PubMed ID: 23458294
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin: examining duration of effect in facial aesthetic applications.
Flynn TC
Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type A therapy for cervical dystonia.
Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
